<DOC>
	<DOCNO>NCT00072332</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , edotecarin cisplatin , use different way stop tumor cell divide stop grow die . Combining edotecarin cisplatin may kill tumor cell . PURPOSE : Phase I trial study effectiveness combine edotecarin cisplatin treat patient advanced metastatic solid tumor .</brief_summary>
	<brief_title>Edotecarin Cisplatin Treating Patients With Advanced Metastatic Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine maximum tolerate dose recommended phase II dose edotecarin administer cisplatin ( administered 2 different schedule ) patient advance metastatic solid tumor . Secondary - Determine safety profile regimen patient . - Determine plasma pharmacokinetics regimen patient . - Determine antitumor activity regimen patient . OUTLINE : This open-label , multicenter , dose-escalation study edotecarin . Patients assign 1 2 schedule . - Schedule A : Patients receive cisplatin IV 30 minute edotecarin IV 1 hour day 1 8 . - Schedule B : Patients receive cisplatin IV 2 hour edotecarin IV 1 hour day 1 . In schedule , course repeat every 3 week absence disease progression unacceptable toxicity . Cohorts 3-6 patient schedule receive escalating dos edotecarin maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . Once MTD determine , 10 additional patient metastatic esophageal gastric cancer receive treatment MTD . Patients follow every 2 month 1 year disease progression . PROJECTED ACCRUAL : A maximum 80 patient ( 40 per schedule ) accrue study .</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis one following : Histologically cytologically confirm active solid tumor malignancy Histologically confirm esophageal gastric cancer* meeting follow criterion : Previously untreated disease Metastatic disease Measurable disease At least 1 unidimensionally measurable lesion least 20 mm conventional technique OR 10 mm spiral CT scan NOTE : *Patients esophageal gastric cancer enrol maximum tolerated dose determine No known brain leptomeningeal disease PATIENT CHARACTERISTICS : Age 18 Performance status ECOG 01 Life expectancy Not specify Hematopoietic Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hemoglobin least 9.0 g/dL Hepatic Bilirubin great 1.5 time upper limit normal ( ULN ) ( regardless liver involvement tumor ) SGOT great 3 time ULN ( 5 time ULN liver involvement tumor ) Albumin least 3.0 g/dL Renal Creatinine great 1.5 mg/dL Cardiovascular None follow within past 12 month : Myocardial infarction Severe/unstable angina Symptomatic congestive heart failure Cerebrovascular accident Transient ischemic attack Deep vein thrombosis Other significant thromboembolic event No ongoing grade 2 great cardiac dysrhythmia No atrial fibrillation Pulmonary No pulmonary embolism within past 12 month Gastrointestinal No active inflammatory bowel disease No partial complete bowel obstruction No chronic diarrhea Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception HIV negative No grade 2 great acute toxic effect No active infection No concurrent acute chronic medical psychiatric condition laboratory abnormality would preclude study participation PRIOR CONCURRENT THERAPY : Biologic therapy No prior treatment follow systemic therapy metastatic cancer* : Antibody therapy Immunotherapy Gene therapy Vaccine therapy Cytokine therapy Inhibitors vascular endothelial growth factor/Flk1 pathway No concurrent sargramostim ( GMCSF ) No concurrent antibody therapy immunotherapy NOTE : *Patients esophageal gastric cancer Chemotherapy No 1 prior chemotherapy regimen metastatic disease* No prior highdose chemotherapy require hematopoietic stem cell rescue No concurrent chemotherapy NOTE : *No prior chemotherapy metastatic disease patient esophageal gastric cancer Endocrine therapy No concurrent hormonal treatment Radiotherapy No prior radiotherapy 25 % bone marrow reserve No prior radiotherapy sole measurable lesion* No concurrent radiotherapy NOTE : *Patients esophageal gastric cancer Surgery More 12 month since prior coronary/peripheral artery bypass graft surgery Other Recovered prior therapy More 6 month since last dose prior adjuvant therapy* No prior treatment follow systemic therapy metastatic cancer* : Cyclooxygenase2 inhibitor Matrix metalloprotease inhibitor Epidermal growth factor receptor inhibitor Other experimental agent No concurrent anticancer therapy No concurrent enrollment another clinical trial No concurrent experimental drug NOTE : *Patients esophageal gastric cancer</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2009</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
	<keyword>stage IV esophageal cancer</keyword>
	<keyword>stage IV gastric cancer</keyword>
</DOC>